Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes.

Autor: Strollo R; Department of Science and Technology for Humans and the Environment, Università Campus Bio-Medico di Roma, Rome, Italy., Vinci C; Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK., Man YKS; Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK., Bruzzaniti S; Institute for Experimental Endocrinology and Oncology 'G. Salvatore', Consiglio Nazionale delle Ricerche, Naples, Italy.; Department of Biology, Università degli Studi di Napoli 'Federico II', Naples, Italy., Piemonte E; Department of Molecular Medicine and Medical Biotechnology, Università degli Studi di Napoli 'Federico II', Naples, Italy., Alhamar G; Department of Medicine, Unit of Endocrinology & Diabetes, Università Campus Bio-Medico di Roma, Rome, Italy., Briganti SI; Department of Medicine, Unit of Endocrinology & Diabetes, Università Campus Bio-Medico di Roma, Rome, Italy., Malandrucco I; The UOSD of Endocrinology and Metabolic Diseases, Azienda Sanitaria Locale (ASL) Frosinone, Frosinone, Italy., Tramontana F; Department of Medicine, Unit of Endocrinology & Diabetes, Università Campus Bio-Medico di Roma, Rome, Italy., Fanali C; Department of Science and Technology for Humans and the Environment, Università Campus Bio-Medico di Roma, Rome, Italy., Garnett J; Centre for Host-Microbiome Interactions, Dental Institute, King's College London, London, UK.; School of Biological and Chemical Sciences, Queen Mary University of London, London, UK., Buccafusca R; School of Biological and Chemical Sciences, Queen Mary University of London, London, UK., Guyer P; Program for Translational Immunology, Benaroya Research Institute, Seattle, WA, USA., Mamula M; Department of Medicine, Yale University School of Medicine, New Haven, CT, USA., James EA; Program for Translational Immunology, Benaroya Research Institute, Seattle, WA, USA., Pozzilli P; Department of Medicine, Unit of Endocrinology & Diabetes, Università Campus Bio-Medico di Roma, Rome, Italy., Ludvigsson J; Division of Pediatrics, Department of Biomedical and Clinical Sciences, Crown Princess Victoria Children's Hospital, Linköping University, Linköping, Sweden., Winyard PG; Institute of Biomedical and Clinical Science, University of Exeter Medical School, St Luke's Campus, Exeter, UK., Galgani M; Institute for Experimental Endocrinology and Oncology 'G. Salvatore', Consiglio Nazionale delle Ricerche, Naples, Italy.; Department of Molecular Medicine and Medical Biotechnology, Università degli Studi di Napoli 'Federico II', Naples, Italy., Nissim A; Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK. a.nissim@qmul.ac.uk.

Publikováno v: Diabetologia [Diabetologia] 2023 Jan; Vol. 66 (1), pp. 132-146. Date of Electronic Publication: 2022 Oct 07.

Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus AdΔΔ through Bcl-2-dependent attenuation of autophagy

Autor: Aguirre-Hernandez, C, Maya-Pineda, H, San Millan, J, Man, YKS, Lu, Y-J, Hallden, G

Anti-apoptotic Bcl-2 is frequently activated in human malignant cells to promote cell survival and inhibit cell death. Replication-selective oncolytic adenoviruses deleted in the functional Bcl-2 homologue E1B19K potently synergise with apoptosis-ind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::855fc2b0d548d2d661e8422cfbac16b1
http://hdl.handle.net/10044/1/69195

Personalized nanovaccines for treating solid cancer metastases.

Autor: Feng, Tang^1,2 (AUTHOR), Hu, Jia^1,3 (AUTHOR), Wen, Jirui⁴ (AUTHOR), Qian, Zhiyong⁵ (AUTHOR), Che, Guowei³ (AUTHOR), Zhou, Qinghua³ (AUTHOR), Zhu, Lingling^1,3 (AUTHOR) zhulingling8262023@126.com

Publikováno v: Journal of Hematology & Oncology. 11/28/2024, Vol. 17 Issue 1, p1-50. 50p.

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.

Autor: Man YKS; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom., Davies JA; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom., Coughlan L; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York., Pantelidou C; Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Blázquez-Moreno A; Department of Immunology and Oncology, Centro Nacional de Biotecnología-Consejo Superior de Investigaciones Científicas, Madrid, Spain., Marshall JF; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, United Kingdom., Parker AL; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom., Halldén G; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom. g.hallden@qmul.ac.uk.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2018 Feb; Vol. 17 (2), pp. 575-587.

CRISPR/Cas9-mediated knock out of ITGB6 in human OSCC cells reduced migration and proliferation ability.

Autor: Geyer, Maximilian¹ (AUTHOR) maximilian.geyer@web.de, Geyer, Fabian¹ (AUTHOR), Reuning, Ute² (AUTHOR), Klapproth, Sarah³ (AUTHOR), Wolff, Klaus-Dietrich¹ (AUTHOR), Nieberler, Markus¹ (AUTHOR)

Publikováno v: Head & Face Medicine. 6/18/2024, Vol. 20 Issue 1, p1-9. 9p.